A Study of Use of Ella®, an Emergency Contraceptive, Under Simulated OTC Conditions

• Status: Completed
• Trial end date: 2018-06-14
• Target enrollment: 0
• Participant gender: Female

Summary

This study is designed to assess whether consumers select and use ella® (ulipristal acetate 30mg), an emergency contraceptive, in a manner consistent with the OTC package directions in an OTC-like setting.

• Phase: Phase 3
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: HRA Pharma
• Treatments: Contraceptives, Postcoital; Ulipristal acetate

Criteria

Inclusion Criteria:

• Women who are self-pay or who are willing to be self-pay for the purposes of the study and who present for emergency contraception only for their own use

Exclusion Criteria:

• Cannot read, speak and understand English

• Cannot see well enough to read information on the label